Exscientia plc (NASDAQ:EXAI) Q1 2024 Earnings Conference Call May 21, 2024 8:30 AM ET Company Participants Chinedu Okeke - Associate Director-Strategy, IR David Hallett - Interim CEO, Chief Scientific Officer Ben Taylor - CFO, Chief Strategy Officer Conference Call Participants Alec Stranahan - Bank of America Vikram Purohit - Morgan Stanley Peter Lawson - Barclays Operator Hello, everyone. My name is Sarah, and I will be your conference operator today. At this time, I would like to welcome everyone to Exsc ...

Exscientia PLC Sponsored ADR (EXAI) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by ...

NEW YORK, May 22, 2024 /PRNewswire/ --WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Exscientia p.l.c (NASDAQ: EXAI) between March 23, 2022 and February 12, 2024, both dates inclusive (the "Class Period"), of the important June 25, 2024 lead plaintiff deadline.SO WHAT: If you purchased Exscientia securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.WHAT TO D ...

技术平台优势 - Exscientia 公司的技术平台强大，有望在人工智能对药物研究产生影响的背景下获得机会[1] - Exscientia 公司在药物研发中采用人工智能技术，可以加速批准过程，缩短上市时间，从而提高投资回报率[5] 人工智能应用 - Exscientia 公司与大数据公司和其他生物技术公司在使用 Gen AI 方面有所区别，专注于特定领域的分子识别[8] - Exscientia 公司已经通过其 Generative AI 平台创造了第六种进入临床阶段的分子，领先于竞争对手[9]

NEW YORK, May 21, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Exscientia plc (NASDAQ: EXAI).Shareholders who purchased shares of EXAI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/exscientia-plc-loss-submission-form/?id=80715&from=4CLASS PERIOD: March 23, 2022 to Februar ...

BENSALEM, Pa., May 17, 2024 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Exscientia p.l.c. ("Exscientia" or the "Company") (NASDAQ: EXAI). Class Period: March 23, 2022 – February 12, 2024 Lead Plaintiff Deadline: June 25, 2024 Investors suffering losses on their Exscientia investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this c ...

NEW YORK, May 16, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Exscientia p.l.c. ("Exscientia" or the "Company") (NASDAQ: EXAI) and certain officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 24-cv05692, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Exscientia securities between March 23, 2022, and Febraury 12, 202 ...

NEW YORK, May 15, 2024 /PRNewswire/ --WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Exscientia p.l.c (NASDAQ: EXAI) between March 23, 2022 and February 12, 2024, both dates inclusive (the "Class Period"), of the important June 25, 2024 lead plaintiff deadline.SO WHAT: If you purchased Exscientia securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.WHAT TO D ...

财务数据和关键指标变化 - 公司在2023年末拥有4.63亿美元的现金和定期存款,为公司提供了至2026年的资金储备 [40] - 2023年全年的净经营现金流出为1.5亿美元,预计2024年的经营现金流出将低于2023年 [41] 各条业务线数据和关键指标变化 - 公司内部正在推进多个高度差异化的小分子肿瘤项目,包括CDK7抑制剂GTA-EXS-617和LSD1抑制剂EXS74539 [7][8][29][34] - 与合作伙伴的多个项目也在不同疾病领域取得进展,如与Sanofi的合作项目取得首个里程碑 [8][37] 各个市场数据和关键指标变化 - 公司的CDK7抑制剂GTA-EXS-617正在进行I/II期临床试验,预计将于2023年下半年进入剂量扩展阶段 [30] - 公司的LSD1抑制剂EXS74539计划于2024年下半年进入临床试验 [34] 公司战略和发展方向及行业竞争 - 公司致力于利用其行业领先的技术平台设计和开发更好的药物,提高药物研发的效率和成功率 [7][13][14][17] - 公司新建的自动化实验设施将与AI驱动的化合物设计进行深度集成,提高整个药物设计和发现价值链的速度、效率和质量 [9][24][25][26] - 公司正在将大语言模型应用于靶点识别和生物学机理分析,提高工作效率和决策质量 [19][20][21][22][23] 管理层对经营环境和未来前景的评论 - 公司在2023年取得了稳步进展,加强了管线重点和技术能力,为未来发展奠定了基础 [43][44] - 公司将继续推进内部项目的临床开发,同时与合作伙伴合作以实现既定目标,并寻求新的合作机会 [44] 问答环节重要的提问和回答 问题1 **Alec Stranahan 提问** 自动化设施对公司的业务影响如何,是否会带来成本和时间上的优势?合作伙伴如何看待这一能力? [48][49] **Dave Hallett 和 Ben Taylor 回答** 自动化设施将带来显著的成本和时间优势,不仅体现在直接成本节约,更在于提高数据质量和加快学习迭代的速度,从而加快整个药物研发过程 [50][51][52][53] 合作伙伴已经开始从中受益,这也是公司未来拓展合作的一大卖点 [51] 问题2 **Vikram Purohit 提问** EXCYTE-2研究如何支持LSD1抑制剂EXS74539的开发?公司未来的合作策略是什么? [68][69] **Mike Krams 和 Ben Taylor 回答** EXCYTE-2研究可以帮助公司进一步确定EXS74539的最佳适应症和组合疗法 [70] 公司未来将更多利用自身管线项目的进展来谈判更有价值的合作,同时也在与科技公司探讨各种形式的合作 [71][72][73]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 13(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...